Literature DB >> 31055050

Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (Prospective Halle Monocytes Study).

Florian Höpfner1, Marrit Jacob2, Christof Ulrich3, Martin Russ4, Andreas Simm5, Rolf E Silber5, Matthias Girndt3, Michel Noutsias4, Karl Werdan4, Axel Schlitt6.   

Abstract

BACKGROUND: Monocytes can be differentiated by the presence of CD14 and CD16 (CD14++CD16-, classical; CD14++CD16+, intermediate and CD14 + CD16++, non-classical monocytes). Recent studies have reported conflicting results regarding an association between subtypes of monocytes as defined by the expression of these two surface markers in atherosclerosis.
METHODS: We investigated subtypes of monocytes in n = 994 patients with angiographically documented coronary artery disease (CAD). We compared total numbers of monocyte subgroups stratified by tertiles with the occurrence of the pre-defined combined endpoint (non-fatal myocardial infarction, cardiovascular death and non-haemorrhagic cerebral insult). Patients were followed up for a minimum of 52 weeks. Classical risk factors of coronary heart disease were included in multivariate analysis.
RESULTS: The primary endpoint occurred 134 times at a median time of 34.5 weeks (IR 10.6/59.6). Intermediate (p = 0.813), non-classical (p = 0.725) and the number of total monocytes (p = 0.626) stratified by tertiles showed no significant association with the combined endpoint. However, a higher absolute number of classical monocytes divided in tertiles was associated with incidence of the combined endpoint {T1 = 8.9% vs T2 = 14.2% vs T3 = 16.0% (p = 0.021)}. When comparing the third with the first tertile of Mo1 population, multivariate analysis showed a hazard ratio of 1.646 (CI: 1.005-2.699, p = 0.048).
CONCLUSIONS: The absolute counts of classical monocytes divided in tertiles are predictive of major adverse cardiac events in patients with CAD. A tremendous shift from classical to intermediate monocytes was also confirmed in patients with CAD. These data highlight the importance of CD14++ monocytes in cardiovascular diseases.
Copyright © 2019 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; CD14; CD16; Cardiovascular disease; Monocytes

Mesh:

Substances:

Year:  2019        PMID: 31055050     DOI: 10.1016/j.hjc.2019.04.012

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  8 in total

1.  Monocyte and macrophage subtypes as paired cell biomarkers for coronary artery disease.

Authors:  Kathryn A Arnold; John E Blair; Jonathan D Paul; Atman P Shah; Sandeep Nathan; Francis J Alenghat
Journal:  Exp Physiol       Date:  2019-07-25       Impact factor: 2.969

Review 2.  Monocyte recruitment and fate specification after myocardial infarction.

Authors:  Kyle I Mentkowski; Lindsey M Euscher; Akshar Patel; B Rita Alevriadou; Jennifer K Lang
Journal:  Am J Physiol Cell Physiol       Date:  2020-09-02       Impact factor: 4.249

3.  Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis.

Authors:  Mikkel Carstensen; Tove Christensen; Morten Stilund; Holger J Møller; Eva L Petersen; Thor Petersen
Journal:  Immunol Cell Biol       Date:  2020-05-05       Impact factor: 5.126

4.  A Correlation Between Monocyte to Lymphocyte Ratio and Long-Term Prognosis in Patients With Coronary Artery Disease After PCI.

Authors:  Feng-Hua Song; Ying-Ying Zheng; Jun-Nan Tang; Wei Wang; Qian-Qian Guo; Jian-Chao Zhang; Yan Bai; Kai Wang; Meng-Die Cheng; Li-Zhu Jiang; Ru-Jie Zheng; Lei Fan; Zhi-Yu Liu; Xin-Ya Dai; Zeng-Lei Zhang; Xiao-Ting Yue; Jin-Ying Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals.

Authors:  Monick Lindenmeyer Guimarães; Fernanda Heloise Côrtes; Diogo Gama Caetano; Marcelo Ribeiro-Alves; Eugênio Damaceno Hottz; Larissa Melo Vilela; Sandra Wagner Cardoso; Brenda Hoagland; Beatriz Grinsztejn; Valdilea Gonçalves Veloso; Mariza Gonçalves Morgado; Patrícia Torres Bozza
Journal:  Sci Rep       Date:  2022-04-21       Impact factor: 4.996

Review 6.  Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.

Authors:  Vijay Chaitanya Ganta; Brian H Annex
Journal:  Expert Opin Ther Targets       Date:  2021-06-17       Impact factor: 6.797

Review 7.  A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives.

Authors:  Gabriela Betlej; Ewelina Bator; Antoni Pyrkosz; Aleksandra Kwiatkowska
Journal:  Genes (Basel)       Date:  2020-06-11       Impact factor: 4.096

8.  Apolipoprotein A1 deficiency in mice primes bone marrow stem cells for T cell lymphopoiesis.

Authors:  Amber B Ouweneel; Myrthe E Reiche; Olga S C Snip; Robbert Wever; Ezra J van der Wel; Frank H Schaftenaar; Soňa Kauerova; Esther Lutgens; Miranda Van Eck; Menno Hoekstra
Journal:  J Cell Sci       Date:  2021-11-16       Impact factor: 5.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.